journal
MENU ▼
Read by QxMD icon Read
search

Journal of Virus Eradication

journal
https://www.readbyqxmd.com/read/30050687/careful-consideration-when-responding-to-new-data-dolutegravir-and-pregnancy
#1
EDITORIAL
C Foster, S Fidler, Egh Lyall, Gpt Taylor
This case highlights the current complexities of managing women in the early stages of pregnancy presenting on dolutegravir-based regimens. When responding to new data, there is an important decision to be made, between the potential, uncertain risk of teratogenicity against the potential increased risk of in utero vertical transmission of HIV-1.
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050686/highlights-from-the-20th-international-symposium-on-hiv-and-emerging-infectious-diseases-isheid-16-18-may-2018-marseille-france-from-hiv-and-comorbidities-to-global-health
#2
EDITORIAL
Christina Psomas, Sabine Kinloch, Caroline Sabin, Vicente Soriano, Caroline Solas, Chloe Orkin, José Bernardino, Adrian Curran, Jean-Pierre Routy, Patricia Enel, Patrick Philibert, Alain Lafeuillade
The 20th International Symposium on HIV and Emerging Infectious Diseases took place in Marseille, France. It had a refreshing European look with reinforced partnerships with the European AIDS Clinical Society and the British HIV Association and with international speakers and participants. Topics included HIV and global health, HIV and hepatitis cure, the microbiome and immunotherapies, clinical research and methodology, as well as chemsex, pre-exposure prophylaxis, sexually transmitted infections and emerging infectious diseases...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050685/report-from-the-international-viral-hepatitis-elimination-meeting-ivhem-17-18-november-2017-amsterdam-the-netherlands-gaps-and-challenges-in-the-who-2030-hepatitis-c-elimination-framework
#3
EDITORIAL
Stephanie Popping, Manal El-Sayed, Jordan Feld, Angelos Hatzakis, Margaret Hellard, Olufunmilayo Lesi, Michael Ninburg, John Ward, Charles Boucher
The current global burden of hepatitis C (HCV) is estimated at 71 million people. The World Health Organization (WHO) has stated that HCV could be eliminated as a public health threat by 2030. A key recommendation to reach this elimination goal is to reduce new infections by 90% and liver-related mortality by 65%. Countries are encouraged by the WHO to develop their own national elimination programmes in order to reach these goals. However, various gaps and challenges, such as the lack of high-quality epidemiological data, stigmatisation, and optimisation of the cascade of care, have arisen in the WHO strategic framework...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050684/keeping-our-core-values-aliv-h-e-holistic-community-led-participatory-and-rights-based-approaches-to-addressing-the-links-between-violence-against-women-and-girls-and-hiv
#4
EDITORIAL
Fiona Hale, Emma Bell, Annie Banda, Betty Kwagala, L Leigh-Ann van der Merwe, Silvia Petretti, Anandi Yuvaraj
There is increasing recognition that violence against women is a barrier to sexual and reproductive health and rights, and a cause and consequence of HIV. In this viewpoint, we describe the recently published Action Linking Initiatives on Violence Against Women and HIV Everywhere (ALIV[H]E) framework [1]. The potential of this framework is explored in terms of it contributing to paradigm change to achieve the sexual and reproductive health rights of women experiencing, or living in contexts of, violence and/or HIV...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050683/the-role-of-the-primary-healthcare-network-in-iran-in-hepatitis-c-virus-elimination-by-2030
#5
EDITORIAL
Masoud Behzadifar, Hasan Abolghasem Gorji, Aziz Rezapour, Nicola Luigi Bragazzi, Seyed Moayed Alavian
The World Health Organization (WHO) has estimated that about 71 million people in the world have chronic hepatitis C virus (HCV) and 399,000 die every year due to cirrhosis and cancer caused by HCV. Despite efforts to prevent and control hepatitis, there are still many barriers. In September 2000, during a summit in New York organised by the United Nations, world leaders agreed on a set of achievable targets within a limited timeframe, with the goal of combating poverty, hunger, disease, illiteracy, destruction of the environment and of improving the status of women by 2015; these were known as the Millennium Development Goals...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050682/maximising-the-global-health-impact-of-future-hiv-cure-related-interventions-through-advance-planning
#6
EDITORIAL
Regina Brown, Steven G Deeks, Nir Eyal
Thinking about public health impact should inform HIV curative investigations. Should an effective HIV cure or sustained viral remission intervention emerge from ongoing investigations, implementation strategies aimed at ensuring global access will be needed if these approaches are to be impactful, and planning accordingly makes sense now. Specifically, we discuss three key access barriers to future cure-related interventions: high cost of the strategy; non-financial challenges to procurement, distribution and point-of-care delivery; and non-adherence and the need for long-term monitoring...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050681/the-need-for-a-european-hepatitis-c-programme-monitoring-resistance-to-direct-acting-antiviral-agents-in-real-life-to-eliminate-hepatitis-c
#7
EDITORIAL
Stephanie Popping, Valeria Cento, Federico García, Francesca Ceccherini-Silberstein, Carole Seguin-Devaux, David Amc Vijver, Charles A Boucher
The World Health Organization (WHO) has declared that hepatitis C virus (HCV) should be eliminated as a public health threat. A key recommendation to reach this elimination goal, is to reduce new infections by 90% and liver-related mortality by 65%. Highly effective direct-acting antiviral agents (DAA) play a major role in this elimination. Unfortunately, DAA treatment fails approximately 2.5-5% of patients, often in the presence of resistance-associated substitutions (RAS). This could eventually lead to a total number of 1...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050680/htlv-1-2-prevalence-in-two-amazonian-communities
#8
EDITORIAL
Elida Cg Mata, Roberto M Bezerra, Aldo A Proietti Júnior, Luana Ks Pamplona, Lilian O Gomes, Valmir C Corrêa, Jordan Sr Caluff, Geanny S Borges, J Casseb, Lib Kanzaki
Introduction: The human T-cell lymphotropic virus type 1 (HTLV-1) is aetiologically linked to myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukaemia (ATL) besides other less incident pathologies, while the type 2 has not been definitively linked to any diseases. Objectives: To determine the HTLV-1/2 seroprevalence in two Brazilian communities in northern Brazil. Methods: In 2010 and 2015, HTLV-1/2 serological surveys were carried out in the Oiapoque county at the Brazilian border with French Guiana and in Santa Cruz do Arari, Marajó Island...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050679/analysis-of-ex-vivo-hiv-1-infection-in-a-controller-discordant-couple
#9
EDITORIAL
Paradise Madlala, Paulien Van de Velde, Barbara Van Remoortel, Sofie Vets, Eric Van Wijngaerden, Kristel Van Laethem, Rik Gijsbers, Rik Schrijvers, Zeger Debyser
Objectives: Elite controllers (EC) are a rare group of individuals living with HIV-1 who naturally control HIV-1 replication to levels below the limit of detection without antiretroviral therapy (ART) and rarely progress to AIDS. The mechanisms contributing to this control remain incompletely elucidated. In the present study, we have assessed whether cellular host factors could modulate HIV-1 replication post-entry in a controller-discordant couple living with HIV-1. Methods: CD4 T cells from a controller-discordant couple, one partner being an EC and the other an HIV-1 progressor (PR), and healthy controls (HC) were isolated, activated and infected with VSV-G pseudotyped yellow fluorescent protein-encoding single-round HIV-1 virus (HIV-YFP)...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050678/investigating-the-role-of-stigma-on-fertility-desire-among-hiv-positive-women-in-bangkok-thailand-a-qualitative-study
#10
EDITORIAL
Natasha Mehta, Jennifer Ho, Phiangjai Boonsuk, Shannon Fuller, Annette H Sohn
Objectives: The Thai Ministry of Public Health is committed to reaching the United Nations' goal of zero new HIV infections, zero AIDS-related deaths, and zero discrimination towards people living with HIV by 2030. While significant progress has been made towards the first two targets, stigma against women living with HIV (WLHIV), particularly in the context of their desire to have and raise children, remains an issue. Methods: We conducted interviews with WLHIV ( n =10) who expressed a desire to have a child or delivered an infant within 2 years of the study date, and key informants (KI) involved in their medical care and social support...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050677/a-decentralised-multidisciplinary-model-of-care-facilitates-treatment-of-hepatitis-c-in-regional-australia
#11
EDITORIAL
Andrew Lee, Josh Hanson, Penny Fox, Greg Spice, Darren Russell, Peter Boyd
Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rates and minimal side effects. Despite the high burden of disease, strategies to ultimately eradicate HCV are being developed. However, the delivery of care in regional settings is challenging and the efficacy of decentralised models of care is incompletely defined. Methods: A prospective cohort study of patients whose treatment was initiated or supervised by Cairns Hospital, a tertiary hospital which provides services to a culturally diverse population across a 380,748 km2 area in regional Australia...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30050676/australasian-society-for-hiv-viral-hepatitis-and-sexual-health-medicine-hiv-pre-exposure-prophylaxis-clinical-guidelines-update-april-2018
#12
EDITORIAL
Edwina Wright, Andrew Grulich, Katy Roy, Mark Boyd, Vincent Cornelisse, Darren Russell, Darryl O'Donnell, Bill Whittaker, Levinia Crooks, Iryna Zablotska
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine's (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control's PrEP guidelines and are designed to: •Support the prescription of PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials•Assist clinicians in the evaluation of patients who are seeking PrEP•Assist clinicians in commencing and monitoring patients on PrEP including PrEP dosing schedules, management of side-effects and toxicity, use of PrEP in pregnancy and in chronic hepatitis B infection and how to cease PrEP Daily PrEP with co-formulated tenofovir and emtricitabine, used continuously or for shorter periods of time, is recommended in these guidelines as a key HIV-prevention option for men who have sex with men (MSM), transgender men and women, heterosexual men and women, and people who inject drugs (PWID) at substantial risk of HIV acquisition...
July 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/30079251/speaker-presentations-of-the-2018-international-symposium-on-hiv-and-emerging-infectious-diseases-isheid
#13
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
May 18, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682309/australasian-society-for-hiv-viral-hepatitis-and-sexual-health-medicine-hiv-pre-exposure-prophylaxis-clinical-guidelines-update-april-2018
#14
EDITORIAL
Edwina Wright, Andrew Grulich, Katy Roy, Mark Boyd, Vincent Cornelisse, Darren Russell, Darryl O'Donnell, Bill Whittaker, Levinia Crooks, Iryna Zablotska
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine's (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control's PrEP guidelines and are designed to: •Support the prescription of PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials•Assist clinicians in the evaluation of patients who are seeking PrEP•Assist clinicians in commencing and monitoring patients on PrEP including PrEP dosing schedules, management of side-effects and toxicity, use of PrEP in pregnancy and in chronic hepatitis B infection and how to cease PrEP Daily PrEP with co-formulated tenofovir and emtricitabine, used continuously or for shorter periods of time, is recommended in these guidelines as a key HIV-prevention option for men who have sex with men (MSM), transgender men and women, heterosexual men and women, and people who inject drugs (PWID) at substantial risk of HIV acquisition...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682308/highlights-from-the-8-th-international-workshop-on-hiv-persistence-during-therapy-12-15-december-2017-miami-fl-usa
#15
EDITORIAL
Christina K Psomas, Alain Lafeuillade, David Margolis, Karl Salzwedel, Mario Stevenson, Nicolas Chomont, Guido Poli, Jean-Pierre Routy
Over 4 days, more than 500 scientists involved in HIV persistence research shared their new unpublished data and designed future perspectives towards ART-free HIV remission. This 8th International Workshop on HIV Persistence followed the format of past conferences but further focused on encouraging participation of young investigators, especially through submission of oral and poster presentations. The topic of the workshop was HIV persistence. Consequently, issues of HIV reservoirs and HIV cure were also addressed...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682307/bioequivalent-pharmacokinetics-for-generic-and-originator-hepatitis-c-direct-acting-antivirals
#16
EDITORIAL
Andrew Hill, Loai Tahat, Mohammed Khalil Mohammed, Rabab Fayez Tayyem, Giten Khwairakpam, Sanjay Nath, James Freeman, Ismahane Benbitour, Sherine Helmy
Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuvir and daclatasvir at low cost. However, generic manufacturers need to demonstrate bioequivalent pharmacokinetics for their DAAs, compared to the originator versions, to fulfil World Health Organization standards for prequalification...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682306/anti-m%C3%A3-llerian-hormone-levels-are-reduced-in-women-living-with-human-immunodeficiency-virus-compared-to-control-women-a-case-control-study-from-copenhagen-denmark
#17
EDITORIAL
Maria Wessman, Anne-Sofie Korsholm, Janne Gasseholm Bentzen, Anders Nyboe Andersen, Magnus Glindvad Ahlström, Terese Lea Katzenstein, Nina Weis
Objectives: Anti-müllerian hormone (AMH) is a marker of ovarian reserve. The purpose of this study was to compare AMH in women living with HIV with an age-matched control group of HIV-uninfected women, and to identify possible variables associated with decreasing AMH levels in women living with HIV. Methods: AMH was measured in frozen EDTA samples from 84 white women living with HIV, aged 20 -40 years, with fully suppressed HIV RNA viral loads for at least 6 months and no hepatitis B or C virus co-infection...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682305/outpatient-directly-observed-therapy-for-hepatitis-c-among-people-who-use-drugs-a-systematic-review-and-meta-analysis
#18
EDITORIAL
Cara L McDermott, Catherine M Lockhart, Beth Devine
Objective:  We conducted a meta-analysis of randomised studies that assessed the effectiveness of directly observed hepatitis C medication therapy delivered in outpatient clinics compared to treatment as usual. Methods:  We completed a systematic literature review up to the end of August 2017, including online databases, study abstracts and references of pertinent articles. We assessed the results of randomised studies using the Cochrane Collaboration risk of bias assessment tool, and observational studies using the ROBINS-I tool...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682304/implementation-of-hepatitis-c-cure-in-australia-one-year-on
#19
EDITORIAL
Jacqueline A Richmond, Jack Wallace
Objectives: Direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) became universally available in Australia in March 2016, with an aim to achieve HCV elimination. Fourteen per cent of Australians with HCV have initiated treatment. The objective of this study was to explore and identify challenges and enablers that have emerged during this initial phase of HCV cure implementation. Methods: Key stakeholders (KS) in primary care, non-government and government sectors were recruited to participate in a telephone-based semi-structured interview to describe challenges and enablers facing individuals with HCV and the healthcare system in implementing HCV cure...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682303/heterogeneity-in-hepatitis-c-treatment-prescribing-and-uptake-in-australia-a-geospatial-analysis-of-a-year-of-unrestricted-treatment-access
#20
EDITORIAL
Nick Scott, Samuel W Hainsworth, Rachel Sacks-Davis, Alisa Pedrana, Joseph Doyle, Amanda Wade, Margaret Hellard
Background and aim: Direct-acting antiviral (DAA) treatments became available for all people living with hepatitis C virus (HCV) in Australia in March 2016. We assess variations in treatment rates and prescribing patterns across Australia's 338 Statistical Area 3 (SA3) geographical units. Methods: Geocoded DAA treatment initiation data were analysed for the period 1 March 2016 to 30 June 2017. Regression models tested associations between the population demographics and healthcare service coverage of geographical areas and (a) their treatment rates; and (b) the proportion of prescriptions written by specialists compared to non-specialists...
April 1, 2018: Journal of Virus Eradication
journal
journal
50095
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"